Video
Dr. Kapur on patient preferences for OAB third-line therapies
Author(s):
“With this study, we gained a better understanding of the features of third line therapy for overactive bladder, that patients find favorable and unfavorable,” says Anjali Kapur, MD.
Video Player is loading.
In this video, Anjali Kapur, MD, shares the take-home message of the recent Neurourology and Urodynamics paper, “An analysis of factors that influence patient preference of third-line therapy for overactive bladder.” Kapur is a urology resident at Renaissance School of Medicine at Stony Brook University, Stony Brook, New York.
Related Videos
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Jason Hafron, MD, considers the future for AI in urology
Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
Investigators evaluate tamsulosin use in pediatric patients
Ruchika Talwar, MD, on how urologists can get involved in advocacy
Chad Ellimoottil, MD, on how urologists should approach telehealth in changing policy environment
How recombinant BCG could ease strain of supply issues
Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
Related Content
